Figure 4From: Local adherent technique for transplanting mesenchymal stem cells as a potential treatment of cartilage defectEx vivo analysis of human synovial mesenchymal stem cell attachment to human cartilage defect. The cartilage defect at 2.5 mm diameter was faced upward, filled with 800 × 103 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI)-labeled human synovial mesenchymal stem cells (MSCs) in 8 μl PBS, and held stationary for 5, 10, 20, and 30 minutes. (a) Macroscopic features of cartilage defects filled with DiI-labeled human synovial MSCs for the indicated time. Bar = 2.5 mm. (b) Cell number attached to the cartilage defects. Data expressed as the mean ± standard deviation (n = 3). (c) Adhesion molecule expressions in cartilage defects filled with synovial MSC suspension for 10 minutes. Bars = 50 μm. Ab, antibody; ICAM-1, intercellular adhesion molecule 1; VCAM-1, vascular adhesion molecule 1. (d) Effects of neutralizing antibodies for adhesion molecules on attachment of human synovial MSCs on human cartilage defects. The cartilage defect was filled with DiI-labeled human synovial MSC suspension with control or neutralizing antibodies. After 10 minutes, the attached cell number was measured. Data expressed as the mean ± standard deviation (n = 3; P < 0.05 by Kruskal–Wallis test). ALCAM, activated leukocyte-cell adhesion molecule.Back to article page